BioNumerik Starts Phase III with Improved Chemo Drug Feb. 8, 2008 By Trista Morrison BioNumerik Pharmaceuticals Inc. started a pivotal Phase III trial comparing Karenitecin (BNP1350) with GlaxoSmithKline plc's Hycamtin (topotecan) in relapsed ovarian cancer. (BioWorld Today)Read More
RSS